Overview

The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients

Status:
Not yet recruiting
Trial end date:
2035-06-01
Target enrollment:
0
Participant gender:
All
Summary
Glaucoma represents a group of conditions that cause damage to the optic nerve and can lead to irreversible vision loss. Current treatments are aimed at lowering intraocular pressure while minimizing medication side effects. Lumify™ (Brimonidine Tartrate Ophthalmic Solution 0.025%) is an FDA-approved medication for alleviating eye redness, a common side effect of glaucoma medications. The purpose of this study is to evaluate the effect of Lumify™ on eye redness, intraocular pressure, and eyelid position in patients with glaucoma who are already using the Brimonidine 0.1%, 0.15% or 0.2% eye drops.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Tulane University
Treatments:
Brimonidine Tartrate
Ophthalmic Solutions
Pharmaceutical Solutions
Criteria
Inclusion Criteria:

- Age > 18 years

- Diagnosis of primary open angle glaucoma

- Willing and able to give informed consent

- Current and greater than 6 weeks of brimonidine 0.2%, 0.15% or 0.1% use

Exclusion Criteria:

- Pregnancy

- Prisoners

- Known allergy or sensitivities to brimonidine

- No surgery within the past 6 months

- No history of lid surgery or botox

- Any other significant ophthalmologic disorder or condition with relevant effect on
ocular redness, IOP, or eyelid position as evaluated by principal investigator

- Inability to sit comfortably for 30 minutes

- Prior use of eye whiteners (eg, vasoconstrictors), decongestants, antihistamines, or
phenylephrine dilating drops within 1 week of study